美的集团
000333 · CN
000333 Research Preview
| Metric | Reading |
|---|---|
| Price | 78.00 |
| Daily move | -1.54% |
| Strategy score | 40/100 (Hold) |
| Trend | Consolidation |
| RSI14 / RSI6 | 38.87 / 26.85 |
| MACD (line / signal / hist) | -0.06 / 0.51 / -0.57 |
| Support (estimated) | 77.53 (+0.61% away) |
| Resistance (estimated) | 85.00 (+8.98% away) |
| 30-session range position | +2.47% (range 77.80-85.90) |
| Data confidence | Medium |
| Indicator | Reading | Read |
|---|---|---|
| MA (5/10/20/60) | 80.07 / 81.65 / 81.26 / 79.35 | Price below all MAs; MA5 < MA20 death cross. Precomputed alignment flagged as mixed. |
| RSI (14/6) | 38.87 / 26.85 | Soft but not washed out; RSI6 deeper into oversold than RSI14. |
| MACD | -0.06 / 0.51 / -0.57 | Bearish: line below signal, below zero, negative histogram, momentum fading. |
| KDJ (K/D/J) | 18.33 / 36.52 / -18.06 | Washed-out; J deeply negative, a setup for a rebound watch rather than confirmation. |
| Bollinger (U/M/L) | 85.00 / 81.26 / 77.53 | Price near lower band (6% of band); band width expanding. |
| ATR14 / % | 2.06 / +2.64% | Moderate volatility relative to price. |
| OBV / 20d slope | 59,967,475 / -22.85% | Distribution pressure; declining accumulation trend. |
| CCI20 | -126.28 | Below -100, indicating downside pressure / oversold territory. |
Confirmed: A bearish-to-consolidating trend backdrop is consistent across MACD (death cross, below zero), MA structure (price under MA20/MA10/MA5, MA5<MA20 death cross), OBV (-22.85% slope, distribution), and CCI (-126.28). Volume confirms selling, with current volume +11.74% above the 20-session average on a down day (量价关系 35/100 Sell).
Conflicted: Mean-reversion indicators disagree with the trend signals. RSI14 (38.87) and Bollinger position (near lower band, 6% of band) both score as Buy (60/100 and 65/100), and KDJ is washed-out with J at -18.06, flagging a possible rebound. This is the core tension: oversold readings vs persistent distribution and a bearish MACD.
Missing: No volume-profile, no longer-horizon (weekly) confirmation, and no custom indicators were supplied, so the rebound-vs-continuation question cannot yet be resolved from the indicator set alone.
| Axis | Reading | Source | Confidence |
|---|---|---|---|
| PE | 13.45 | AkShare THS financial abstract | Medium |
| PB | 2.55 | AkShare THS financial abstract | Medium |
| PEG proxy | 0.95 | StockKit scenario model | Medium |
| Fair value range | Bear CNY 107.7 / Base CNY 137.39 / Bull CNY 173.62 | StockKit DCF scenario model | Medium |
| Base fair-value gap | +76.1% | StockKit DCF scenario model | Medium |
| 5Y growth forecast | Bear +8.13% / Base +14.13% / Bull +20.13% | StockKit scenario model | Medium |
| Revenue | CNY 458.50B | AkShare THS financial abstract | Medium |
| Net income | CNY 43.95B | AkShare THS financial abstract | Medium |
| EPS | 5.8 | AkShare THS financial abstract | Medium |
| Book value per share | 30.55 | AkShare THS financial abstract | Medium |
| Gross margin | +25.57% | AkShare THS financial abstract | Medium |
| Net margin | +9.81% | AkShare THS financial abstract | Medium |
The PEG proxy (0.95) and the fair-value range (Base CNY 137.39, +76.1% above the current 78.00) are StockKit internal scenario outputs computed from public financial history, not analyst consensus targets, and should be read as model forecasts. Reported fundamentals (income data as of 2025-12-31) show PE 13.45, PB 2.55, net margin +9.81%, and EPS 5.8 on revenue of CNY 458.50B. The gap between a low-teens PE and a large modeled fair-value premium is the item most dependent on the model's growth assumptions (Base +14.13% over 5Y), which carries the medium-confidence caveat. EV/EBITDA, dividend yield, market cap, and a 52-week range were not supplied and are omitted.
| Date | Headline | Source | Relevance |
|---|---|---|---|
| 2026-06-08 | Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 | GlobeNewswire | Low / likely unrelated. This headline concerns Novartis pharmaceutical data and shows no clear link to 美的集团 (a home-appliance maker). Treat as noise unless a connection is later confirmed. |
| 2026-06-06 | Top 10 Shenzhen Stock Exchange Picks for 2026: Innovation and Growth | Ibtimes.com.au | Indirect. A market-list piece referencing Shenzhen-listed names; 000333 trades on the SZSE, so it may provide context, but no company-specific fact is stated in the supplied data. |
Missing data: No confirmed company-specific catalysts (earnings dates, guidance, dividends, product or M&A announcements) were supplied. The catalyst calendar is effectively empty in this dataset, so the near-term path is driven by price action and technicals rather than known events. This section is low confidence on news.
| Source | Status | Reading | Confidence |
|---|---|---|---|
| NewsAPI headline coverage | 2 headlines | GlobeNewswire x1, Ibtimes.com.au x1 | Low |
| Social sentiment | Not connected | No social sentiment conclusion is drawn | Low |
No provider-level sentiment score was returned for this symbol, and social sources are not connected, so no Reddit, X, StockTwits, or local-forum reading is available. Headline coverage is sparse (2 items, one likely unrelated), which means sentiment cannot be meaningfully gauged from this dataset. Overall sentiment confidence is Low.
| Scenario | Trigger condition | What would confirm it | What would invalidate it |
|---|---|---|---|
| Base (consolidation) | Price holds the 77.53 support / lower-band region and chops between support and MA20 (~81.26). Composite score 40/100, Hold. | Stabilization above 77.53 with RSI14 lifting off 38.87 and MACD histogram (-0.57) contracting. | Decisive close below 77.53 or a break above 85.00 resistance. |
| Upside (oversold rebound) | Oversold mean-reversion plays out: RSI6 (26.85), KDJ J (-18.06), and lower-band position (6% of band) snap back. | Reclaim of MA20 (81.26) then MA10 (81.65), MACD line crossing above signal, OBV slope turning up from -22.85%. | Failure to reclaim MA20 and renewed lower-band pressure with rising down-volume. |
| Downside (continuation) | Distribution persists: OBV slope -22.85%, MACD below zero, down-day volume +11.74% above average. | Sustained break of 77.53 / lower band on expanding volume and ATR. | Reclaim of 77.53 as support and a higher low with improving RSI. |
| Risk | Evidence | Trigger | Monitoring action |
|---|---|---|---|
| Trend continuation lower | MACD -0.06 below signal 0.51, below zero; MA5<MA20 death cross; CCI -126.28 | Close below 77.53 support | Watch the 77.53 / lower-band hold daily |
| Distribution / weak demand | OBV slope -22.85%; price down on volume +11.74% above 20d average | Further OBV decline with down-days | Track OBV slope and up/down volume balance |
| False rebound (oversold trap) | RSI14 38.87 and Bollinger Buy signals conflict with bearish trend signals | Rejection at MA20 (81.26) after a bounce | Confirm any bounce with a MACD cross above signal |
| Resistance overhead | Resistance 85.00 is +8.98% away; MA10/MA20 cluster ~81.3-81.7 | Failure at the MA cluster | Watch reaction at MA20/MA10 on any rally |
| Model-vs-market valuation gap | Base fair-value +76.1% is a StockKit DCF model output, not consensus | Growth assumptions not borne out by reported fundamentals | Reassess if reported growth diverges from Base +14.13% |
| Thin information base | 2 headlines (one likely unrelated); no sentiment score | New material news arriving against the technical setup | Re-run when company-specific catalysts appear |
1. The 77.53 support / lower Bollinger band: does price hold or break (+0.61% away today)? 2. RSI14 (38.87) and RSI6 (26.85): turning up off oversold, or extending lower? 3. MACD histogram (-0.57): contracting toward a cross, or widening negative? 4. MA20 reclaim test at ~81.26 on any rebound, then MA10 at ~81.65. 5. OBV 20-session slope (-22.85%): flattening/turning up, or still falling. 6. Volume behavior: today's +11.74% above-average down-volume - does down-volume persist? 7. New company-specific news or sentiment data, given the currently thin and partly unrelated headline set.
This brief is generated from the supplied StockKit dataset only and is a public-facing research preview, not personalized investment advice. Levels are watch levels for observation, not instructions to act. Confidence is Medium overall, with lower confidence on news and sentiment (sparse headlines, one likely unrelated, no sentiment score) and on the valuation upside, which is derived from StockKit internal scenario/DCF models rather than analyst consensus. No returns are promised. Items absent from the dataset (e.g., EV/EBITDA, dividend yield, market cap, 52-week range, earnings dates) were omitted rather than estimated.
MA5<MA20死叉
MACD死叉,MACD在零轴下方,动能减弱
RSI14=39偏低
接近下轨,可能反弹,带宽扩张中
价跌放量(1.1x),抛压沉重
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
GlobeNewswire · 2026-06-08
Top 10 Shenzhen Stock Exchange Picks for 2026: Innovation and Growth
Ibtimes.com.au · 2026-06-06
Research boundary
StockKit organizes market data and model output for research workflows. It does not provide personalized advice or trade instructions. Verify important information with primary sources before any investment decision.